Literature DB >> 30665868

Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma.

Ghassan K Abou-Alfa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30665868     DOI： 10.1016/S1470-2045(19)30009-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report.

Authors:  Tiago Biachi de Castria; Laura Tang; Marcello Moro Queiroz; Beatriz Mendes Awni; Viktoriya Paroder; Ali Shamseddine; Giovanni Mendonca Bariani; Deborah Mukherji; Charbel F Matar; Gustavo Dos Santos Fernandes; Ashwaq El-Olayan; Fouad Sabatin; Rawad Elias; Ranju Gupta; Yelena Y Janjigian; Ghassan K Abou-Alfa
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses.

Authors:  Crisanta H Ilagan; Debra A Goldman; Mithat Gönen; Victoria G Aveson; Michelle Babicky; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; T Peter Kingham; Ghassan K Abou-Alfa; Karen T Brown; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-15       Impact factor: 4.339

3.  Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Rajesh Kaldate; Robin Kate Kelley; Tim Meyer; Lorenza Rimassa; Philippe Merle; Joong-Won Park; Thomas Yau; Stephen L Chan; Jean-Frederic Blanc; Vincent C Tam; Albert Tran; Vincenzo Dadduzio; David W Markby; Ann-Lii Cheng; Anthony B El-Khoueiry; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2020-07-07       Impact factor: 12.531

Review 4.  Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.

Authors:  Daneng Li; Sabrina Sedano; Rebecca Allen; Jun Gong; May Cho; Sunil Sharma
Journal:  Cancers (Basel)       Date:  2019-06-18       Impact factor: 6.639

5.  Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.

Authors:  James J Harding; Richard K Do; Amin Yaqubie; Ann Cleverly; Yumin Zhao; Ivelina Gueorguieva; Michael Lahn; Karim A Benhadji; Robin K Kelley; Ghassan K Abou-Alfa
Journal:  Cancer Med       Date:  2021-04-02       Impact factor: 4.452

Review 6.  Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.

Authors:  Thomas Yau; David Tai; Stephen Lam Chan; Yi-Hsiang Huang; Su Pin Choo; Chiun Hsu; Tan To Cheung; Shi-Ming Lin; Wei Peng Yong; Joycelyn Lee; Thomas Leung; Tracy Shum; Cynthia S Y Yeung; Anna Yin-Ping Tai; Ada Lai Yau Law; Ann-Lii Cheng; Li-Tzong Chen
Journal:  Liver Cancer       Date:  2022-06-17       Impact factor: 12.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.